DaShenLin Pharmaceutical Group Co., Ltd.

SHSE:603233 Voorraadrapport

Marktkapitalisatie: CN¥18.2b

DaShenLin Pharmaceutical Group Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Guoqiang Ke

Algemeen directeur

CN¥2.3m

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO5.8yrs
Eigendom CEO0.02%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur1.8yrs

Recente managementupdates

Recent updates

Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

Sep 30
Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Aug 20
DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Jun 17
Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Jun 09
Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

May 21
Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

May 06
Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Apr 09
Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

Mar 17
Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

CEO

Guoqiang Ke (42 yo)

5.8yrs

Tenure

CN¥2,308,800

Compensatie

Mr. Guoqiang Ke is General Manager of DaShenLin Pharmaceutical Group Co., Ltd. from February 28, 2019 and serves as DIrector since February 03, 2023. He was Deputy General Manager of DaShenLin Pharmaceutic...


Bestuursleden

NaamPositieTenureCompensatieEigendom
Guoqiang Ke
GM & Director1.8yrsCN¥2.31m0.025%
CN¥ 4.5m
Qun Fei Tan
Deputy GM & Director1.8yrsCN¥2.05m0.024%
CN¥ 4.3m
Zhi Hui Chen
Chairman of Supervisory Board & Deputy Director of Human Resources Department - Guangdong Provinceno datageen gegevens0.012%
CN¥ 2.1m
Yun Feng Ke
Chairman of the Boardno dataCN¥2.49m21.3%
CN¥ 3.9b
Guo Liu
Independent Directorno dataCN¥73.40kgeen gegevens
Zu Yao Su
Independent Directorno dataCN¥80.00kgeen gegevens
Jie Li
Directorno datageen gegevensgeen gegevens
Li Ping Lu
Independent Directorno dataCN¥80.00kgeen gegevens
Jinshu Shi
Staff Supervisorno datageen gegevens0.00055%
CN¥ 99.8k
Wensheng Chen
Supervisor1.8yrsgeen gegevensgeen gegevens

1.8yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 603233 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw bestuur.